| Project/Area Number |
24791842
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Ophthalmology
|
|---|
| Research Institution | Tokyo Medical and Dental University |
|---|
Principal Investigator |
MOROHOSHI KEI 東京医科歯科大学, 医学部附属病院, 非常勤講師 (60598415)
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | 加齢黄斑変性 / 自己抗体 / バイオマーカー / 自己免疫 / 血管新生 / 加齢黄斑 / 抗網膜抗体 |
|---|
| Outline of Final Research Achievements |
Age-related macular degeneration (AMD) is currently the leading cause of blindness and recent studies have indicated that autoimmunity, in particular, anti-retinal/choroidal autoantibodies affects the development of AMD.
In this study, several novel autoantibodies to metabolic enzymes, including pyruvate kinase M2 (PKM2), aldolase C and glutamine synthetase, were identified by mass spectrometry (LC-MS/MS) and antigen microarray in the sera of AMD patients and IgGs purified from the patients inhibited activity of those enzymes in a dose dependent manner. Moreover, mice with laser-induced choroidal neovascularization (CNV) demonstrated a similar autoantibody profile to AMD patients and increase of PKM2 expression with strong IgG deposition was observed in the CNV lesion. Hence, our data suggested that anti-PKM2 IgG antibody could be a candidate biomarker for AMD and a potential molecular target for novel therapeutic strategies of the disease.
|
